CDMO AGC Bio has picked up a second site in Colorado, buying a cell and gene therapy facility in Longmont from Novartis. The 622,000 square-foot facility in Longmont – north of Denver, Colorado – will become part of AGC Biologics’ ever-growing manufacturing footprint, and will go hand-in-hand with its cell and gene therapy site in Milan, Italy, added through the €240 million ($284 million) acquisition of Molmed last year. “The Longmont facility fits perfectly into AGC’s long-term growth and expansion…

The facility in New Albany, Ohio will support assembly and packaging for a range of Amgen’s medicines, the firm says. The $365 million investment will see Amgen construct a 270,000 square-foot facility in New Albany, creating around 400 jobs ranging from technicians, engineers, quality assurance, quality control, administrative and management positions. “The facility will assemble, label and package vials and syringes for a wide variety of Amgen medicines,” Amgen spokeswoman Megan Fox told BioProcess Insider. “This new final product advanced…

Fujifilm Diosynth Biotechnologies (FDB) will double cell culture production for recombinant vaccines in the US and increase gene therapy production in the UK ten-fold as part of its latest investment plans. The ¥90 billion ($850 million) expansion will increase capacity across a range of modalities on both sides of the Atlantic. As well as doubling cell culture production for recombinant vaccines in the US, the firm will grow capacity at its Teeside, UK site to increase gene therapy production ten-fold,…